Daewoong Pharma
KRX:069620
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Daewoong Pharma
KRX:069620
|
KR |
|
Exopharm Ltd
ASX:EX1
|
AU |
|
Excel Industries Ltd
NSE:EXCELINDUS
|
IN |
|
Hardide PLC
LSE:HDD
|
UK |
|
Almawave SpA
MIL:AIW
|
IT |
|
Y
|
Yulho Co Ltd
KOSDAQ:072770
|
KR |
|
Ircon International Ltd
NSE:IRCON
|
IN |
|
Rocky Brands Inc
NASDAQ:RCKY
|
US |
|
Gaumont SA
PAR:GAM
|
FR |
|
Jewett-Cameron Trading Company Ltd
NASDAQ:JCTC
|
US |
|
Freshii Inc
TSX:FRII
|
CA |
Wall Street
Price Targets
Price Targets Summary
Daewoong Pharma
According to Wall Street analysts, the average 1-year price target for
Daewoong Pharma
is 234 600 KRW
with a low forecast of 212 100 KRW and a high forecast of 262 500 KRW.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Daewoong Pharma's stock price target?
Price Target
234 600
KRW
According to Wall Street analysts, the average 1-year price target for
Daewoong Pharma
is 234 600 KRW
with a low forecast of 212 100 KRW and a high forecast of 262 500 KRW.
What is Daewoong Pharma's Revenue forecast?
Projected CAGR
6%
For the last 14 years the
compound annual growth rate for
Daewoong Pharma's revenue is
6%.
The projected
CAGR
for the next 3 years is
6%.
What is Daewoong Pharma's Operating Income forecast?
Projected CAGR
13%
For the last 14 years the
compound annual growth rate for
Daewoong Pharma's operating income is
9%.
The projected
CAGR
for the next 3 years is
13%.
What is Daewoong Pharma's Net Income forecast?
Projected CAGR
1%
For the last 14 years the
compound annual growth rate for
Daewoong Pharma's net income is
10%.
The projected
CAGR
for the next 3 years is
1%.
